Pfizer Inc. and Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (enfortumab vedotin-ejfv) plus Keytruda (pembrolizumab) as neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC) regardless of cisplatin eligibility. This approval marks the first platinum-free regimen for this patient population, supported by Phase 3 EV-304 clinical trial data presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium.

The approval expands upon the November 2025 FDA approval for cisplatin-ineligible patients. The EV-304 trial demonstrated that the combination significantly reduced the risk of tumor recurrence, progression, or death by 47% compared to standard neoadjuvant gemcitabine and cisplatin chemotherapy. Additionally, the regimen showed a 35% reduction in the risk of death compared to neoadjuvant chemotherapy.

Clinical Trial Results

In the EV-304 trial, patients were randomized to receive surgery with neoadjuvant and adjuvant PADCEV plus pembrolizumab or surgery with neoadjuvant chemotherapy. The treatment was administered as a planned total of 9 cycles of PADCEV and 17 cycles of pembrolizumab split before and after surgery.

The safety profile was consistent with prior experience, with Grade 3 or higher adverse events occurring in 75.7% of patients treated with the combination compared to 67.2% with chemotherapy.

Regulatory and Strategic Context

Christopher Hoimes, Director of the Bladder Cancer Program at Duke Cancer Institute and EV-304 Principal Investigator, emphasized the importance of delivering the regimen across both neoadjuvant and adjuvant phases to reduce recurrence and improve survival. Aamir Malik, Executive Vice President and Chief U.S. Commercial Officer at Pfizer, highlighted the approval as a historic turning point providing the first platinum-free combination shown to improve survival over the current standard of care.

Moitreyee Chatterjee-Kishore, Head of Oncology Development at Astellas, noted that the regimen is the first platinum-free treatment option in nearly 25 years to outperform standard chemotherapy. The collaboration between Pfizer, Astellas, and Merck focuses on evaluating the combination of PADCEV and Keytruda in patients eligible for cisplatin-based chemotherapy.

HSBC downgraded Pfizer Inc. to Hold from Buy on Monday, citing weakened near-term re-rating prospects despite an attractive dividend yield and long-term oncology ambitions. Analysts Rajesh Kumar and Dylan Whitfield lowered their target forecast to $28 from $32, pointing to increased uncertainty around key pipeline assets and recent executive leadership changes. The original bullish thesis relied on increased R&D focus, a dividend yield of roughly 6%, and management's goal of delivering high single-digit revenue growth between 2028 and 2032. However, the analysts now believe those growth expectations are unlikely to be validated in the near term.

Oncology Pipeline Delay Weighs On Growth Outlook

A key factor behind the downgrade was a reduction in the probability of success for sigvotatug vedotin (SV) to 40% following its Phase 3 setback in non-small cell lung cancer (NSCLC). The analysts also raised the stock's beta to 0.85 from 0.78, contributing to the lower price target. According to the note, Pfizer's long-term growth outlook depends heavily on the success of SV, atirmociclib, a VEGF-bispecific oncology program, and, to a lesser extent, its obesity portfolio. However, meaningful catalysts for these programs are expected closer to 2027 rather than in the second half of 2026, leaving investors with few near-term events to resolve the ongoing growth debate.

In the meantime, analysts expect the effects of MFN pricing, IRA-related changes, and loss-of-exclusivity pressures to become increasingly visible.

Management Changes Add Another Layer Of Uncertainty

The report highlighted recent executive leadership changes as another reason for caution. With a new chief financial officer and chief strategy officer joining the leadership team under the current CEO, analysts believe investors may wait for greater clarity on the company's approach to capital allocation and dividend discipline. While Pfizer's valuation appears attractive relative to its medium-term earnings potential, the stock could remain inexpensive unless the company delivers successful pipeline outcomes. The NSCLC setback for sigvotatug vedotin increases uncertainty around future catalysts and could negatively affect investor perception of management's capital allocation if impairments related to Seagen's intangible assets emerge.